InvestorsHub Logo
Followers 45
Posts 16218
Boards Moderated 0
Alias Born 09/16/2012

Re: None

Wednesday, 03/20/2024 10:52:49 AM

Wednesday, March 20, 2024 10:52:49 AM

Post# of 705562
NICE decision on Sickle Cell.


>>According to the draft guidance – published earlier this month – the NICE committee noted the cost-effectiveness estimate for the treatment was higher than what would be acceptable for NHS use.

The guidance said it also needed more information to “address the uncertainties in the clinical and economic evidence” and has requested “additional data” from manufacturers.

The Sickle Cell Society, which supports people with the disease said it “disappointed” by decision.

https://www.voice-online.co.uk/news/2024/03/20/sickle-cell-patients-hopes-dashed-as-nhs-decides-against-gene-therapy/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News